Schering-Plough to build four new facilities in Singapore for $450 million

Schering-Plough's wholly-owned subsidiary in Singapore has announcedplans to build four new facilities in the country at a cost of $450 million, bringing the company's total investment in Singapore to approximately $750 million. S-P said that its construction plans include a multi-product bulk manufacturing plant, a biotechnology sterile manufacturing facility, an oral solid dosage unit and an R&D base.

John Nine, S-P's vice president, said that the new facilities will strengthen the company's ability to compete in worldwide markets by providing additional production capacity needed for new lines. He added that "Singapore's strong commitment to the life sciences was instrumental in our decision to invest here," noting that the country offers a highly-skilled and educated workforce, "as well as excellent infrastructure, transportation and communication facilities.''

New facility to produce ezetimibe